Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic HCT for Peripheral T Cell Lymphoma
NCT03922724Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2019
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial of allogeneic hematopoietic stem cells in peripheral T-cell lymphoma (PTCL) (5 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival at 1 year. Started Apr 2019; status: active, not recruiting.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03922724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03922724.